Peripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancer

被引:23
作者
Berghella, AM [1 ]
Contasta, I [1 ]
Pellegrini, P [1 ]
Del Beato, T [1 ]
Adorno, D [1 ]
机构
[1] CNR, Ist Tipizzaz Tissutale & Problemi Dialisi, I-67100 Laquila, Italy
关键词
tumor markers; cytokines; immunological parameters; colorectal cancer;
D O I
10.1089/10849780252824064
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In cancer, the extent to which the disease has spread is probably the most important factor in determining patient prognosis. Hence practical and non-invasive methods are needed to identify disease stage. In a previous paper we showed how diagnostic and prognostic indices for disease progression could be defined by evaluating parameters in peripheral blood. The aim of this study, was to identify further serum parameters that could be used. Serum levels of interferon (IFN)gamma, interleukin (1L)4, IL8, IL7, IL1beta tumor necrosis factor (TNF)alpha, granulocyte macrophage-colony stimulating factor (GM-CSF), soluble (s) IL2 receptor (R) and sIL6R were studied but only levels of IL4, sIL2R, IL8 and IL7 were found to be significant and would therefore be of use in defining diagnostic and prognostic indices for disease progression. In further detail, our results indicate that when serum levels of sIL2R<522 U/ml, IL4<159 pg/ml and IL8>339 pg/ml there is a 95% probability that the disease is in stage I or II where there is no infiltration of lymph nodes; when serum levels of sIL2Rgreater than or equal to522 Ug/ml, 159 pg/mlless than or equal toIL4 less than or equal to319 pg/nd, IL8less than or equal to339 pg/ml and IL7<54 pg/ml, there is a 95% probability that the disease is in stage III and the tumor has invaded the lymph nodes; when the serum levels of IL4greater than or equal to431pg/ml and IL7greater than or equal to54 pg/ml, there is a 95% probability, that the disease is in stage IV and there is metastasis.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 29 条
  • [1] ADERKA D, 1991, CANCER RES, V51, P5602
  • [2] Anand M, 1998, HEMATOL ONCOL, V16, P143
  • [3] The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back
    Berghella, AM
    Pellegrini, P
    Del Beato, T
    Marini, M
    Tomei, E
    Adorno, D
    Casciani, CU
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 45 (05) : 241 - 249
  • [4] Prognostic significance of immunological evaluation in colorectal cancer
    Berghella, AM
    Pellegrini, P
    DelBeato, T
    Maccarone, D
    Adorno, D
    Casciani, CU
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1996, 11 (06) : 355 - 361
  • [5] IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer
    Berghella, AM
    Pellegrini, P
    DelBeato, T
    Adorno, D
    Casciani, CU
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (04) : 265 - 272
  • [6] BERGHELLA AM, 1994, CANCER IMMUNOL IMMUN, V38, P160, DOI 10.1007/BF01525636
  • [7] Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy
    Brunetti, G
    Bossi, A
    Baiardi, P
    Jedrychowska, I
    Pozzi, U
    Bacchella, L
    Bernardo, G
    [J]. LUNG CANCER, 1999, 23 (01) : 1 - 9
  • [8] Relationships between the activity of MMP1/TIMP1 enzymes and the TH1/TH2 cytokine network
    Contasta, I
    Berghella, AM
    Pellegrini, P
    Del Beato, T
    Casciani, CU
    Adorno, D
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1999, 14 (06) : 465 - 475
  • [9] Immunological implications of alterations in the c-Ki-ras and p53 genes in the stepwise progression of colorectal cancer: Indications for the improvement of prognosis, biotherapy treatment and tumor biology understanding
    Contasta, I
    Pellegrini, P
    Berghella, AM
    Del Beato, T
    Canossi, A
    Maccarone, D
    Papola, F
    Adorno, D
    Casciani, CU
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (06) : 385 - 393
  • [10] Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer
    Contasta, I
    Pellegrini, P
    Berghella, AM
    DelBeato, T
    Canossi, A
    DiRocco, M
    Adorno, D
    Casciani, CU
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1996, 11 (06) : 373 - 383